Table 3

Associations of KRAS mutation status with clinicopathological and molecular characteristics in 153 patients
n (%) KRAS wild type KRAS mutated P-value
136(89%) 17(11%)
Age
Mean 63.38 60.71 0.293
Median 62.00 62.00
Range 47-83 49-69
Histological subtype
Mucinous 5(3.7) 7(41.2) <0.001
Serous 87(64.0) 3(17.6)
Endometroid 30(22.1) 5(29.4)
Other 14(10.3) 2(11.8)
Differentiation grade
Well-moderate 36(26.5%) 11(64.7) 0.001
Poor 100(73.5) 6(35.3)
Clinical Stage
I 20(16.0) 6(40.0) 0.088
II 16(12.8) 2(13.3)
III 70(56.0) 4(26.7)
IV 19(15.2) 3(20.0)
Missing 11 15
ER
≤10% 56/43.1) 11(64.7) 0.092
>10% 74(56.9) 6(35.3)
Missing 6 0
PR
≤10% 111(84.1) 10(62.5) 0.035
>10% 21(15.9) 6(37.5)
Missing 4 1
AR
≤10% 112(82.4) 13(76.5) 0.554
>10% 24(17.6) 4(23.5)
Missing 0 0
Chek1
Low 36(28.8) 8(53.3) 0.053
High 89(71.2) 7(46.7)
Missing 11 2
Chek2
Low 43(33.6) 9(56.2) 0.075
High 85(66.4) 7(43.8)
Missing 8 1

Nodin et al.

Nodin et al. Diagnostic Pathology 2013 8:106   doi:10.1186/1746-1596-8-106

Open Data